• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Vaxcyte (PCVX) Is Down 9.7% After Steeper Q1 Losses And Accelerated R&D Spending

    Simply Wall St·05/20/2026 18:31:02
    Listen to the news
    • Vaxcyte, Inc. recently reported first-quarter 2026 results showing a net loss of US$320.62 million, with basic loss per share from continuing operations of US$2.30, both higher than the same period a year earlier.
    • This sharp year-on-year increase in losses highlights how aggressively Vaxcyte is spending to advance its vaccine pipeline and manufacturing capabilities while still pre-revenue.
    • We’ll now examine how this significantly higher quarterly net loss reshapes Vaxcyte’s existing investment narrative and risk-reward balance.

    The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Vaxcyte Investment Narrative Recap

    To own Vaxcyte, you need to believe its broad pneumococcal vaccine platform will eventually translate today’s heavy spending into meaningful future products and revenue. The sharp step up in Q1 2026 net loss to US$320.62 million underscores how quickly cash can be consumed while the company remains pre revenue, which keeps funding needs and spending discipline as the most immediate risk, even as the main near term catalyst remains upcoming VAX 31 Phase 3 readouts.

    Against this backdrop, the recent completion of enrollment in the OPUS 1 and OPUS 2 Phase 3 trials is particularly relevant, because it reinforces that Vaxcyte’s higher quarterly loss is tied directly to advancing the pivotal program intended to support a VAX 31 BLA package. These adult trials, together with OPUS 3 and the infant studies, are central to any future revenue path, so their outcomes will likely matter far more than a single quarter’s loss trajectory.

    Yet against this potential, the pace of losses and future cash needs are also something investors should be aware of...

    Read the full narrative on Vaxcyte (it's free!)

    Vaxcyte’s narrative projects $224.6 million revenue and $28.1 million earnings by 2029. This implies an earnings increase of about $795 million from -$766.6 million today.

    Uncover how Vaxcyte's forecasts yield a $109.00 fair value, a 123% upside to its current price.

    Exploring Other Perspectives

    PCVX 1-Year Stock Price Chart
    PCVX 1-Year Stock Price Chart

    The most cautious analysts were already projecting only about US$15.3 million of revenue and US$1.7 million of earnings by 2029, so when you set that against Q1’s US$320.62 million loss and the binary risk around late stage PCV data, you can see how their narrative paints a far more pessimistic picture that some readers may still want to explore further.

    Explore 3 other fair value estimates on Vaxcyte - why the stock might be worth over 3x more than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Searching For A Fresh Perspective?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.